 | • レポートコード：MR2211MG12615 • 出版社/出版日：Market Monitor Global / 2022年11月 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（納期：2-3日） • 産業分類：製薬・ヘルスケア |
| Single User | ￥481,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥625,300 (USD4,225) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査資料は次の情報を含め、抗体薬物複合体受託製造のグローバル市場規模と予測を記載しています。・抗体薬物複合体受託製造のグローバル市場：売上、2017年-2022年、2023年-2028年 ・抗体薬物複合体受託製造のグローバル市場：販売量、2017年-2022年、2023年-2028年 ・世界のトップ5企業、2021年 抗体薬物複合体受託製造のグローバル市場規模は2021年に000Mドルと評価され、予測期間中に000％のCAGRで2028年までに000Mドルに達すると予測されています。米国市場は2021年に000Mドルと推定されており、中国は2028年までに000Mドルに達すると予測されています。「IgG1」セグメントは今後6年間、000%のCAGRで2028年までに000Mドルに成長すると予測されています。 抗体薬物複合体受託製造のグローバル主要企業は、Lonza Group、 Piramal Pharma Solutions、 Abbvie、 Novasep、 Merck、 Cambrex Corporation、 Recipharm、 Thermo Fisher Scientific、 Cerbios-Pharma、 Sterling Pharma Solutions、 ADC Biotechnology、 Ajinomoto Bio-Pharma Services、 BOC Sciences、 BSP Pharmaceuticals、 CARBOGEN AMCIS、 Goodwin Biotechnologyなどです。2021年にトップ5企業がグローバル売上シェアの約000%を占めています。 マーケットモニターグローバル（MMG）社は、抗体薬物複合体受託製造のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の抗体薬物複合体受託製造市場：タイプ別、2017年-2022年、2023年-2028年 世界の抗体薬物複合体受託製造市場：タイプ別市場シェア、2021年 ・IgG1、IgG2、IgG4 世界の抗体薬物複合体受託製造市場：用途別、2017年-2022年、2023年-2028年 世界の抗体薬物複合体受託製造市場：用途別市場シェア、2021年 ・固形がん、血液がん 世界の抗体薬物複合体受託製造市場：地域・国別、2017年-2022年、2023年-2028年 世界の抗体薬物複合体受託製造市場：地域別市場シェア、2021年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における抗体薬物複合体受託製造のグローバル売上、2017年-2022年 ・主要企業における抗体薬物複合体受託製造のグローバル売上シェア、2021年 ・主要企業における抗体薬物複合体受託製造のグローバル販売量、2017年-2022年 ・主要企業における抗体薬物複合体受託製造のグローバル販売量シェア、2021年 さらに、当レポートは主要企業のプロファイルを提示します。 Lonza Group、 Piramal Pharma Solutions、 Abbvie、 Novasep、 Merck、 Cambrex Corporation、 Recipharm、 Thermo Fisher Scientific、 Cerbios-Pharma、 Sterling Pharma Solutions、 ADC Biotechnology、 Ajinomoto Bio-Pharma Services、 BOC Sciences、 BSP Pharmaceuticals、 CARBOGEN AMCIS、 Goodwin Biotechnology ************************************************************* ・調査・分析レポートの概要 抗体薬物複合体受託製造市場の定義 市場セグメント 世界の抗体薬物複合体受託製造市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の抗体薬物複合体受託製造市場規模 世界の抗体薬物複合体受託製造市場規模：2021年 VS 2028年 世界の抗体薬物複合体受託製造市場規模と予測 2017年-2028年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの抗体薬物複合体受託製造の売上 グローバルトップ3およびトップ5企業、2021年売上ベース グローバル企業の抗体薬物複合体受託製造製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：IgG1、IgG2、IgG4 抗体薬物複合体受託製造のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：固形がん、血液がん 抗体薬物複合体受託製造の用途別グローバル売上・予測 ・地域別市場分析 地域別抗体薬物複合体受託製造市場規模 2021年と2028年 地域別抗体薬物複合体受託製造売上・予測 北米市場 - アメリカの抗体薬物複合体受託製造市場規模2017年-2028年 - カナダの抗体薬物複合体受託製造市場規模2017年-2028年 - メキシコの抗体薬物複合体受託製造市場規模2017年-2028年 ヨーロッパ市場 - ドイツの抗体薬物複合体受託製造市場規模2017年-2028年 - フランスの抗体薬物複合体受託製造市場規模2017年-2028年 - イギリスの抗体薬物複合体受託製造市場規模2017年-2028年 - イタリアの抗体薬物複合体受託製造市場規模2017年-2028年 - ロシアの抗体薬物複合体受託製造市場規模2017年-2028年 アジア市場 - 中国の抗体薬物複合体受託製造市場規模2017年-2028年 - 日本の抗体薬物複合体受託製造市場規模2017年-2028年 - 韓国の抗体薬物複合体受託製造市場規模2017年-2028年 - 東南アジアの抗体薬物複合体受託製造市場規模2017年-2028年 - インドの抗体薬物複合体受託製造市場規模2017年-2028年 南米市場 - ブラジルの抗体薬物複合体受託製造市場規模2017年-2028年 - アルゼンチンの抗体薬物複合体受託製造市場規模2017年-2028年 中東・アフリカ市場 - トルコの抗体薬物複合体受託製造市場規模2017年-2028年 - イスラエルの抗体薬物複合体受託製造市場規模2017年-2028年 - サウジアラビアの抗体薬物複合体受託製造市場規模2017年-2028年 - UAEの抗体薬物複合体受託製造市場規模2017年-2028年 ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Lonza Group、 Piramal Pharma Solutions、 Abbvie、 Novasep、 Merck、 Cambrex Corporation、 Recipharm、 Thermo Fisher Scientific、 Cerbios-Pharma、 Sterling Pharma Solutions、 ADC Biotechnology、 Ajinomoto Bio-Pharma Services、 BOC Sciences、 BSP Pharmaceuticals、 CARBOGEN AMCIS、 Goodwin Biotechnology ... |
This report contains market size and forecasts of Antibody Drug Conjugates Contract Manufacturing in Global, including the following market information:
Global Antibody Drug Conjugates Contract Manufacturing Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Antibody Drug Conjugates Contract Manufacturing market was valued at US$ million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
IgG1 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Antibody Drug Conjugates Contract Manufacturing include Lonza Group, Piramal Pharma Solutions, Abbvie, Novasep, Merck, Cambrex Corporation, Recipharm, Thermo Fisher Scientific and Cerbios-Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antibody Drug Conjugates Contract Manufacturing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Antibody Drug Conjugates Contract Manufacturing Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Antibody Drug Conjugates Contract Manufacturing Market Segment Percentages, by Type, 2021 (%)
IgG1
IgG2
IgG4
Global Antibody Drug Conjugates Contract Manufacturing Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Antibody Drug Conjugates Contract Manufacturing Market Segment Percentages, by Application, 2021 (%)
Solid Tumors
Hematological Malignancies
Global Antibody Drug Conjugates Contract Manufacturing Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Antibody Drug Conjugates Contract Manufacturing Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Antibody Drug Conjugates Contract Manufacturing revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Antibody Drug Conjugates Contract Manufacturing revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Lonza Group
Piramal Pharma Solutions
Abbvie
Novasep
Merck
Cambrex Corporation
Recipharm
Thermo Fisher Scientific
Cerbios-Pharma
Sterling Pharma Solutions
ADC Biotechnology
Ajinomoto Bio-Pharma Services
BOC Sciences
BSP Pharmaceuticals
CARBOGEN AMCIS
Goodwin Biotechnology
1 Introduction to Research & Analysis Reports
1.1 Antibody Drug Conjugates Contract Manufacturing Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Antibody Drug Conjugates Contract Manufacturing Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Antibody Drug Conjugates Contract Manufacturing Overall Market Size
2.1 Global Antibody Drug Conjugates Contract Manufacturing Market Size: 2021 VS 2028
2.2 Global Antibody Drug Conjugates Contract Manufacturing Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Antibody Drug Conjugates Contract Manufacturing Players in Global Market
3.2 Top Global Antibody Drug Conjugates Contract Manufacturing Companies Ranked by Revenue
3.3 Global Antibody Drug Conjugates Contract Manufacturing Revenue by Companies
3.4 Top 3 and Top 5 Antibody Drug Conjugates Contract Manufacturing Companies in Global Market, by Revenue in 2021
3.5 Global Companies Antibody Drug Conjugates Contract Manufacturing Product Type
3.6 Tier 1, Tier 2 and Tier 3 Antibody Drug Conjugates Contract Manufacturing Players in Global Market
3.6.1 List of Global Tier 1 Antibody Drug Conjugates Contract Manufacturing Companies
3.6.2 List of Global Tier 2 and Tier 3 Antibody Drug Conjugates Contract Manufacturing Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type – Global Antibody Drug Conjugates Contract Manufacturing Market Size Markets, 2021 & 2028
4.1.2 IgG1
4.1.3 IgG2
4.1.4 IgG4
4.2 By Type – Global Antibody Drug Conjugates Contract Manufacturing Revenue & Forecasts
4.2.1 By Type – Global Antibody Drug Conjugates Contract Manufacturing Revenue, 2017-2022
4.2.2 By Type – Global Antibody Drug Conjugates Contract Manufacturing Revenue, 2023-2028
4.2.3 By Type – Global Antibody Drug Conjugates Contract Manufacturing Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Antibody Drug Conjugates Contract Manufacturing Market Size, 2021 & 2028
5.1.2 Solid Tumors
5.1.3 Hematological Malignancies
5.2 By Application – Global Antibody Drug Conjugates Contract Manufacturing Revenue & Forecasts
5.2.1 By Application – Global Antibody Drug Conjugates Contract Manufacturing Revenue, 2017-2022
5.2.2 By Application – Global Antibody Drug Conjugates Contract Manufacturing Revenue, 2023-2028
5.2.3 By Application – Global Antibody Drug Conjugates Contract Manufacturing Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region – Global Antibody Drug Conjugates Contract Manufacturing Market Size, 2021 & 2028
6.2 By Region – Global Antibody Drug Conjugates Contract Manufacturing Revenue & Forecasts
6.2.1 By Region – Global Antibody Drug Conjugates Contract Manufacturing Revenue, 2017-2022
6.2.2 By Region – Global Antibody Drug Conjugates Contract Manufacturing Revenue, 2023-2028
6.2.3 By Region – Global Antibody Drug Conjugates Contract Manufacturing Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country – North America Antibody Drug Conjugates Contract Manufacturing Revenue, 2017-2028
6.3.2 US Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.3.3 Canada Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.3.4 Mexico Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.4 Europe
6.4.1 By Country – Europe Antibody Drug Conjugates Contract Manufacturing Revenue, 2017-2028
6.4.2 Germany Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.4.3 France Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.4.4 U.K. Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.4.5 Italy Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.4.6 Russia Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.4.7 Nordic Countries Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.4.8 Benelux Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.5 Asia
6.5.1 By Region – Asia Antibody Drug Conjugates Contract Manufacturing Revenue, 2017-2028
6.5.2 China Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.5.3 Japan Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.5.4 South Korea Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.5.5 Southeast Asia Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.5.6 India Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.6 South America
6.6.1 By Country – South America Antibody Drug Conjugates Contract Manufacturing Revenue, 2017-2028
6.6.2 Brazil Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.6.3 Argentina Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Revenue, 2017-2028
6.7.2 Turkey Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.7.3 Israel Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.7.4 Saudi Arabia Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
6.7.5 UAE Antibody Drug Conjugates Contract Manufacturing Market Size, 2017-2028
7 Players Profiles
7.1 Lonza Group
7.1.1 Lonza Group Corporate Summary
7.1.2 Lonza Group Business Overview
7.1.3 Lonza Group Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.1.4 Lonza Group Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.1.5 Lonza Group Key News
7.2 Piramal Pharma Solutions
7.2.1 Piramal Pharma Solutions Corporate Summary
7.2.2 Piramal Pharma Solutions Business Overview
7.2.3 Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.2.4 Piramal Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.2.5 Piramal Pharma Solutions Key News
7.3 Abbvie
7.3.1 Abbvie Corporate Summary
7.3.2 Abbvie Business Overview
7.3.3 Abbvie Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.3.4 Abbvie Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.3.5 Abbvie Key News
7.4 Novasep
7.4.1 Novasep Corporate Summary
7.4.2 Novasep Business Overview
7.4.3 Novasep Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.4.4 Novasep Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.4.5 Novasep Key News
7.5 Merck
7.5.1 Merck Corporate Summary
7.5.2 Merck Business Overview
7.5.3 Merck Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.5.4 Merck Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.5.5 Merck Key News
7.6 Cambrex Corporation
7.6.1 Cambrex Corporation Corporate Summary
7.6.2 Cambrex Corporation Business Overview
7.6.3 Cambrex Corporation Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.6.4 Cambrex Corporation Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.6.5 Cambrex Corporation Key News
7.7 Recipharm
7.7.1 Recipharm Corporate Summary
7.7.2 Recipharm Business Overview
7.7.3 Recipharm Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.7.4 Recipharm Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.7.5 Recipharm Key News
7.8 Thermo Fisher Scientific
7.8.1 Thermo Fisher Scientific Corporate Summary
7.8.2 Thermo Fisher Scientific Business Overview
7.8.3 Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.8.4 Thermo Fisher Scientific Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.8.5 Thermo Fisher Scientific Key News
7.9 Cerbios-Pharma
7.9.1 Cerbios-Pharma Corporate Summary
7.9.2 Cerbios-Pharma Business Overview
7.9.3 Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.9.4 Cerbios-Pharma Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.9.5 Cerbios-Pharma Key News
7.10 Sterling Pharma Solutions
7.10.1 Sterling Pharma Solutions Corporate Summary
7.10.2 Sterling Pharma Solutions Business Overview
7.10.3 Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.10.4 Sterling Pharma Solutions Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.10.5 Sterling Pharma Solutions Key News
7.11 ADC Biotechnology
7.11.1 ADC Biotechnology Corporate Summary
7.11.2 ADC Biotechnology Business Overview
7.11.3 ADC Biotechnology Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.11.4 ADC Biotechnology Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.11.5 ADC Biotechnology Key News
7.12 Ajinomoto Bio-Pharma Services
7.12.1 Ajinomoto Bio-Pharma Services Corporate Summary
7.12.2 Ajinomoto Bio-Pharma Services Business Overview
7.12.3 Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.12.4 Ajinomoto Bio-Pharma Services Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.12.5 Ajinomoto Bio-Pharma Services Key News
7.13 BOC Sciences
7.13.1 BOC Sciences Corporate Summary
7.13.2 BOC Sciences Business Overview
7.13.3 BOC Sciences Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.13.4 BOC Sciences Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.13.5 BOC Sciences Key News
7.14 BSP Pharmaceuticals
7.14.1 BSP Pharmaceuticals Corporate Summary
7.14.2 BSP Pharmaceuticals Business Overview
7.14.3 BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.14.4 BSP Pharmaceuticals Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.14.5 BSP Pharmaceuticals Key News
7.15 CARBOGEN AMCIS
7.15.1 CARBOGEN AMCIS Corporate Summary
7.15.2 CARBOGEN AMCIS Business Overview
7.15.3 CARBOGEN AMCIS Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.15.4 CARBOGEN AMCIS Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.15.5 CARBOGEN AMCIS Key News
7.16 Goodwin Biotechnology
7.16.1 Goodwin Biotechnology Corporate Summary
7.16.2 Goodwin Biotechnology Business Overview
7.16.3 Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Major Product Offerings
7.16.4 Goodwin Biotechnology Antibody Drug Conjugates Contract Manufacturing Revenue in Global Market (2017-2022)
7.16.5 Goodwin Biotechnology Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer